A Phase 3 Multi-Center, Open Label Study Evaluating the Long Term Safety of SB204 Once Daily in the Treatment of Acne Vulgaris

Trial Profile

A Phase 3 Multi-Center, Open Label Study Evaluating the Long Term Safety of SB204 Once Daily in the Treatment of Acne Vulgaris

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 May 2017

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions
  • Sponsors Novan Inc
  • Most Recent Events

    • 12 May 2017 According to a Novan media release, NDA, submission targeted in the first quarter of 2018.
    • 27 Apr 2017 According to a Novan media release, the company expects to report additional safety data from this trial in 3Q 2017.
    • 14 Nov 2016 According to a Novan media release, based on successful completion of this and two other studies (see profile 261357 and 254425) the company is targeting submission of a new drug application for SB204 to the U.S. Food and Drug Administration by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top